Lung Cancer
Conditions
Interventions
Advanced Non-small Cell Lung Cancer Group:N/A
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Stage IIIB-IV NSCLC patients with histologically confirmed uncommon EGFR mutations (except single 19del/L858R EGFR mutations); 2. Detailed diagnosis, treatment and follow-up data are available; 3. Patients who receive EGFR TKIs or chemotherapy in first-line setting for a period of time that allows assessment of the efficacy (chemotherapy >= 2 cycles, targeted therapy >= 28 days); 4. According to the RECIST1.1 criteria, there are measurable lesions (the long diameter of the tumor lesion on the CT scan is greater than 10 mm, and the short diameter of the lymph node on the CT scan is greater than 15 mm), and the measurable lesion has not received local treatment such as radiotherapy or cryotherapy).
Exclusion criteria
Exclusion criteria: 1.The type of EGFR mutation has not been clearly diagnosed. 2.Patients who have not completed the prescribed treatment cycle or have not undergone regular follow-up (at least once every 2 months) to determine whether the disease has progressed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS;overall survival, OS; | — |
Countries
China
Contacts
Public ContactHuang Meijuan
West China Hospital, Sichuan University
Outcome results
None listed